SB's ReQuip Launched In USA
SmithKline Beecham has launched its non-ergoline dopamine D2 agonist,ReQuip (ropinirole) in the USA for the treatment of the signs and symptoms of Parkinson's disease. The company received clearance to market ReQuip from the US Food and Drug Administration earlier this year (Marketletter September 29).
ReQuip is licensed for use in patients with early Parkinson's (without levodopa) and in patients with advanced Parkinson's (with levodopa). One study, in 147 patients with early Parkinson's, demonstrated that 44% of the ropinirole-treated group did not require levodopa supplementation over a 12-month period, compared to 22.4% of the placebo group.
ReQuip has been made available in five different doses (0.25mg, 0.5mg, 1mg, 2mg and 5mg) at a wholesale acquisition cost "significantly less than older, first-generation ergoline dopamine agonists," says the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze